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Abstract
Background: Spinal muscular atrophy (SMA) is the leading genetic cause of infant death. It is caused by
mutations/deletions of the survival motor neuron 1 (SMN1) gene and is typified by the loss of spinal cord motor
neurons, muscular atrophy, and in severe cases, death. The SMN protein is ubiquitously expressed and various
cellular- and tissue-specific functions have been investigated to explain the specific motor neuron loss in SMA. We
have previously shown that the RhoA/Rho kinase (ROCK) pathway is misregulated in cellular and animal SMA
models, and that inhibition of ROCK with the chemical Y-27632 significantly increased the lifespan of a mouse
model of SMA. In the present study, we evaluated the therapeutic potential of the clinically approved ROCK
inhibitor fasudil.
Methods: Fasudil was administered by oral gavage from post-natal day 3 to 21 at a concentration of 30 mg/kg
twice daily. The effects of fasudil on lifespan and SMA pathological hallmarks of the SMA mice were assessed and
compared to vehicle-treated mice. For the Kaplan-Meier survival analysis, the log-rank test was used and survival
curves were considered significantly different at P < 0.05. For the remaining analyses, the Student’s two-tail t test
for paired variables and one-way analysis of variance (ANOVA) were used to test for differences between samples
and data were considered significantly different at P < 0.05.
Results: Fasudil significantly improves survival of SMA mice. This dramatic phenotypic improvement is not
mediated by an up-regulation of Smn protein or via preservation of motor neurons. However, fasudil
administration results in a significant increase in muscle fiber and postsynaptic endplate size, and restores normal
expression of markers of skeletal muscle development, suggesting that the beneficial effects of fasudil could be
muscle-specific.
Conclusions: Our work underscores the importance of muscle as a therapeutic target in SMA and highlights the
beneficial potential of ROCK inhibitors as a therapeutic strategy for SMA and for other degenerative diseases
characterized by muscular atrophy and postsynaptic immaturity.
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Background
As the leading genetic cause of infant deaths, spinal
muscular atrophy (SMA) is a devastating and incurable
neuromuscular disorder [1,2]. SMA affects 1 in 6,000 to
10,000 births and results from deletions or mutations in
the survival motor neuron 1 (SMN1)g e n e[ 1 - 3 ] .T h e
primary pathological hallmark of SMA is the loss of
lower motor neurons from the spinal cord and corre-
sponding muscular atrophy with subsequent paralysis
and in most severe cases, death [1,2].
The complete loss of the SMN protein is embryonic
lethal [4]. In humans however, a recent duplication
event in chromosome 5 has given rise to the centro-
meric SMN2 gene [3]. While both SMN1 and SMN2
genes differ by only a few nucleotides, a critical C to T
substitution lies within position 6 of SMN2 exon 7 [5,6].
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exon 7, giving rise to the biologically unstable SMNΔ7
protein [3,5]. Although the SMN2 gene produces predo-
minantly the SMNΔ7 protein, a small amount of full-
length SMN is still produced [3]. Thus, the number of
SMN2 gene copies in SMA patients is a key modifier of
disease severity [3,7,8].
One of the major hurdles in SMA is to understand how
the loss of a ubiquitously expressed protein leads to the
specific loss of spinal cord motor neurons. Work from var-
ious research groups has identified distinct roles for SMN
in neurodevelopment, neuromaintenance, RNA metabo-
lism, at the neuromuscular junction (NMJ) and in skeletal
muscle (reviewed in [9]). As of yet however, none of these
various functions of the SMN protein have been recog-
nized as being solely responsible for SMA pathogenesis.
Work from our laboratory has shown that Smn deple-
tion in cellular and mouse models results in altered
expression and localization of a number of regulators of
actin cytoskeletal dynamics [10-12]. Indeed, analysis of
spinal cords from SMA mice revealed a significant
increase in active RhoA (RhoA-GTP) [12], a major
upstream regulator of the actin cytoskeleton [13]. RhoA-
GTP signaling in neuronal cells modulates various cellu-
lar functions such as growth, neurite formation, polari-
zation, regeneration, branching, pathfinding, guidance
and retraction (reviewed in [14,15]). Our previous work
demonstrated that administration of the RhoA/Rho
kinase (ROCK) inhibitor Y-27632 [16] leads to a dra-
matic increase in survival in an intermediate mouse
model of SMA [12]. Recently Nölle et al.d e m o n s t r a t e d
that knockdown of Smn in PC12 cells affects the phos-
phorylation state of downstream effectors of ROCK,
supporting the value of the ROCK pathway as a thera-
peutic target for SMA pathogenesis [17].
In the present work, we have treated SMA mice with
fasudil, a ROCK inhibitor approved for US clinical trials.
We show that fasudil dramatically improves the lifespan
and increases muscle fiber size in Smn
2B/- SMA mice.
Furthermore, we report for the first time that ROCK inhi-
bition restores normal expression of markers of skeletal
muscle development in SMA mice. Our study highlights
the beneficial effects of ROCK inhibition not only for
SMA pathogenesis but also for any degenerative disease
that has NMJ and skeletal muscle development defects.
Importantly, as fasudil is currently being used in US Food
and Drug Administration (FDA)-approved clinical trials
for other disorders, re-purposing it is an exciting and feasi-
ble therapeutic approach for the treatment of SMA.
Methods
Animal models
The Smn
2B/- mice were established in our laboratory
and maintained in our animal facility on a C57BL/6 ×
CD1 hybrid background. The 2B mutation consists of a
substitution of three nucleotides in the exon splicing
enhancer of exon 7 [18,19]. The Smn knock-out allele
was previously described by Schrank et al. [20] and Smn
+/- mice were obtained from The Jackson Laboratory
(Bar Harbor, Maine, USA). All animal procedures were
performed in accordance with institutional guidelines
(Animal Care and Veterinary Services, University of
Ottawa).
Fasudil administration
Fasudil (LC Laboratories; Woburn, Massachusetts, USA)
was diluted in water and administered by a modified
oral gavage procedure [21] to Smn
2B/- and Smn
2B/+ mice
from post-natal day (P)3 to P21. The three fasudil
dosage regimens were as follows: low dose (30 mg/kg
once daily), medium dose (30 mg/kg twice daily), and
high dose (30 mg/kg twice daily from P3 to P6; 50 mg/
kg twice daily from P7 to P13; 75 mg/kg twice daily
from P14 to P21). Vehicle-treated animals received
water. Survival and weight were monitored daily.
Antibodies
The primary antibodies used were as follows: mouse
anti-actin (1:800; Fitzgerald; Acton, Massachusetts,
USA), mouse anti-Smn (1:5000; BD Transduction
Laboratories; Mississauga, Ontario, Canada), rabbit anti-
phosphorylated cofilin (1:250; Chemicon; Billerica, Mas-
sachusetts, USA), rabbit anti-cofilin (1:500; Millipore;
Billerica, Massachusetts, USA), rabbit anti-phosphory-
lated cofilin 2 (1:500; Cell Signaling; Danvers, Massachu-
setts, USA), rabbit anti-cofilin 2 (1:500; Millipore),
mouse anti-myogenin (1:250; BD Transduction Labora-
tories), rabbit anti-HB9 (1:50; Abcam; Cambridge, Mas-
sachusetts, USA), mouse anti-2H3 (1:250;
Developmental Studies Hybridoma Bank; Iowa City,
Iowa, USA) and mouse anti-SV2 (1:250; Developmental
Studies Hybridoma Bank). The secondary antibodies
used were as follows: horseradish peroxidase (HRP)-con-
jugated goat anti-mouse IgG (1:5000; Bio-Rad; Missis-
sauga, Ontario, Canada), HRP-conjugated goat anti-
rabbit IgG (1:5000; Bio-Rad), DyLight goat anti-mouse
(1:250; Jackson ImmunoResearch; West Grove, Pennsyl-
vania, USA), goat anti-rabbit biotin-SP-conjugated
(1:200; Dako; Burlington, Ontario, Canada)), streptavi-
din-Cy3-conjugated (1:600; Jackson ImmunoResearch)
and Alexa Fluor 680 goat anti-mouse (1:5000; Molecular
Probes; Burlington, Ontario, Canada). The a-bungaro-
toxin (BTX) conjugated to tetramethylrhodamine iso-
thiocyanate was from Molecular Probes (5 μg/mL).
Immunoblot analysis
Equal amounts of spinal cord and tibialis anterior (TA)
muscle tissue extracts were separated by electrophoresis
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cellulose membranes (Amersham; Baie d’Urfe, Quebec,
Canada). The membranes were blocked in 5% non-fat
milk in TBST (10 mM Tris-HCl pH 8.0, 150 mM NaCl,
and 0.1% Tween 20 (Sigma; Oakville, Ontario, Canada)).
Membranes were incubated overnight at 4°C with pri-
mary antibody, followed by a one-hour incubation with
the secondary antibody. All washes were performed with
TBST. Signals were visualized using the ECL or the ECL
plus detection kit (Amersham). Exposure times were
chosen based on the saturation of the highest amounts
of protein.
Hematoxylin and eosin staining
Spinal cord (L1-L2 lumbar regions) and TA muscle sec-
tions (5 μm) were deparaffinized in xylene and fixed in
100% ethanol. Following a rinse in water, samples were
stained in hematoxylin (Fisher; El Paso, Texas, USA) for
three minutes, rinsed in water, dipped 40 times in a solu-
tion of 0.02% HCl in 70% ethanol and rinsed in water
again. The sections were stained in a 1% eosin solution
(BDH; Billerica, Massachusetts, USA) for one minute,
dehydrated in ethanol, cleared in xylene and mounted
with Permount (Fisher). Images were taken with a Zeiss
Axioplan2 microscope, with a 20× objective.
Quantitative assays were performed on three mice for
each genotype and five sections per mouse. Motor neu-
rons were identified by their shape and size (> 10 μmi n
diameter) in the same designated area of the ventral
horn region of the spinal cord. Every fifth section was
analyzed and the subsequent totals were multiplied by
five to give an estimate of total motor neuron number.
Only motor neurons with visible nuclei were counted so
as to prevent double-counting. For TA quantitative
assays, the area of muscle fiber within designated
regions of the TA muscle sections was measured using
the Zeiss AxioVision software.
Immunohistochemistry
For immunohistochemistry, spinal cord sections were
first deparaffinized in xylene (3 × 10 minutes), fixed in
100% ethanol (2 × 10 minutes), rehydrated in 95% and
75% ethanol (5 seconds each) and placed for 5 minutes in
1 M Tris-HCl pH 7.5. Sections were then placed in boil-
ing sodium citrate antigen retrieval buffer (10 mM
sodium citrate, 0.05% Tween 20, pH 6.0) for 20 minutes
in the microwave. The sections were rinsed for 10 min-
utes under running cold tap water and incubated for 2
hours at room temperature (RT) in blocking solution
(TBLS (10% NaN3), 20% goat serum, 0.3% Triton X-100).
This was followed by an overnight incubation at 4°C with
the primary antibody. Subsequently, sections were incu-
bated for 1 hour at RT with the biotinylated rabbit anti-
body followed by a 1 hour incubation at RT with
streptavidin-Cy3. All washes were done with PBS.
Hoechst (1:1000) was added to the last PBS wash fol-
lowed by the slides being mounted in fluorescent mount-
ing medium (Dako). Images were taken with a Zeiss
confocal microscope, with a 20× objective, equipped with
filters suitable for Cy3/Hoechst fluorescence.
Neuromuscular junction immunohistochemistry
Transversus abdominis (TVA) and TA muscle sections
were labeled by immunohistochemistry to allow quantifi-
cation of neuromuscular innervation as described pre-
viously [12,22]. Briefly, TVA muscles were immediately
dissected from recently sacrificed mice and fixed in 4%
paraformaldehyde (Electron Microscopy Science; Hat-
field, Pennsylvania, USA) in PBS for 15 minutes. Post-
synaptic acetylcholine receptors were labeled with aBTX
for 10 minutes. Muscles were then permeabilized in 2%
TritonX for 30 minutes and blocked in 4% bovine serum
albumin/1% TritonX in PBS for 30 minutes before incu-
bation overnight in primary antibodies and visualized
with DyLight-conjugated secondary antibodies. Whole
TA muscles were dissected and fixed in 4% paraformal-
dehyde. Following the removal of connective tissue, the
TA muscles were incubated with aBTX Alexa Fluor 555
conjugate for 20 minutes at RT. Whole TVA muscle and
a thin filet of TA muscle were mounted in Dako fluores-
cent mounting media. Images were taken with a Zeiss
confocal microscope equipped with filters suitable for
fluorescein isothiocyanate (FITC)/Cy3/fluorescence.
Categorization of pre- and postsynaptic morphologies
was performed as previously reported [23].
Pen test
Balance and strength were assessed using the pen test as
described [24]. Mice were placed on a suspended pen at
different time-points (P12, 14, 17 and 21). The latency
to fall from the pen was measured with a plateau of 30
seconds. At each time-point, individual mice were
assessed three consecutive times.
Statistical methods
All statistical analyses were performed using the Graph-
Pad Prism software. For the Kaplan-Meier survival ana-
lysis, the log-rank test was used and survival curves
were considered significantly different at P <0 . 0 5 .
When appropriate, the Student’st w o - t a i lt test for
paired variables and one-way ANOVA were used to test
for differences between samples and data were consid-
ered significantly different at P < 0.05.
Results
Fasudil increases lifespan of Smn
2B/- mice
The Smn
2B allele harbors a sequence change in the exon
splicing enhancer of exon 7 of the murine Smn gene,
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protein [18,19]. The Smn
2B allele in combination with
the knockout allele results in an intermediate SMA
mouse model (Smn
2B/-) with a median lifespan of 30
days that displays motor neuron loss, neuromuscular
defects and immature NMJs [23]. We have previously
shown that the ROCK inhibitor Y-27632 dramatically
improved the lifespan of Smn
2B/- mice [12]. Since Y-
27632 has not been approved for clinical use, we set out
to determine if the ROCK inhibitor, fasudil, which has
been approved for US clinical trials [25], would have
similar beneficial effects on the Smn
2B/- mice.
Treating the Smn
2B/- mice by gavage twice daily (30
mg/kg dose) from P3 to P21 led to a significant increase
in lifespan when compared to vehicle-treated Smn
2B/-
mice (Figure 1A). Indeed, 57% of fasudil-treated Smn
2B/-
mice survived over 300 days while the median survival
of vehicle-treated Smn
2B/- mice is 30.5 days (Figure 1A).
A lower dose of fasudil had no effect while a higher
dose was accompanied by a non-negligible toxicity
(Additional file 1). Interestingly, both vehicle- and fasu-
dil-treated Smn
2B/- mice showed a similar arrest in
weight gain after P10 (Figure 1B). When assessing
strength and balance via the pen test [24], both vehicle-
and fasudil-treated Smn
2B/- mice had short latencies to
fall from the pen (Figure 1C). Thus, while fasudil signifi-
cantly increased the lifespan of the Smn
2B/- mice, it did
not influence the weight loss or the neuromuscular
weakness that typifies this SMA mouse model [23].
However, when comparing mice past weaning age, we
find that fasudil-treated Smn
2B/- mice are better
groomed, move about more freely in the cage and dis-
play a less severe neurological phenotype than vehicle-
treated Smn
2B/- mice (Additional file 2). Additionally,
despite their initial compromised body size and neuro-
muscular function, surviving fasudil-treated Smn
2B/-
female mice are able to reproduce, as exemplified by a
female that was euthanized because of dystocia (Figure
1A). The dystocia-linked death, however, highlights the
breeding limitations in these aging fasudil-treated mice
that still exhibit an SMA neuromuscular phenotype.
Fasudil activity in the spinal cord does not prevent motor
neuron loss in Smn
2B/- mice
The main goal of using fasudil as a therapeutic strategy
is to compensate for the increased levels of RhoA-GTP
in the spinal cords of the Smn
2B/- mice [12]. In order to
investigate the mechanisms by which fasudil exerts its
beneficial effects, we investigated its activity and impact
on motor neuron loss in the spinal cord. Spinal cord
extracts from P21 fasudil-treated Smn
2B/- mice showed a
reduction in phosphorylated cofilin, a downstream effec-
tor of ROCK [26,27], when compared to vehicle-treated
SMA mice (Figure 2A), demonstrating that oral
administration of fasudil efficiently delivers the drug to
the CNS and leads to an efficient inhibition of ROCK
activity.
To investigate if the beneficial effects of fasudil admin-
istration are mediated through an increase in Smn
expression, we compared Smn protein levels in P21
spinal cords of wild type, vehicle-treated and fasudil-
treated Smn
2B/- mice. This comparison shows that fasu-
dil does not lead to a significant upregulation of Smn
expression (Figure 2B) and further suggests that fasudil
acts via an Smn-independent pathway to improve the
survival of Smn
2B/- mice.
As a major hallmark of SMA is loss of lower motor
neuron cell bodies from the spinal cord, we assessed the
effect of fasudil on the motor neuron loss previously
characterized in the Smn
2B/- mouse model [11,23].
Quantification of the number of motor neuron cell
bodies in the ventral horn region of L1-L2 lumbar spinal
cord sections revealed similar significant reductions in
both vehicle- and fasudil-treated Smn
2B/- mice compared
to wild type controls (Figure 2C, D). This implies that
the beneficial effects observed following fasudil adminis-
tration are not mediated via a preservation of motor
neuron cell bodies. It is therefore possible that fasudil
acts on other SMA-afflicted tissues and/or compart-
ments that subsequently influence the functionality of
the surviving motor neurons.
Fasudil increases skeletal muscle fiber size
In addition to motor neuron degeneration, SMA is also
typified by muscular atrophy [1,2]. In recent years, sev-
eral intrinsic pathologies and defective molecular path-
ways have been reported in SMA muscle ([28-30] and
JGB, unpublished data). Furthermore, we have pre-
viously demonstrated that the ROCK inhibitor Y-27632
leads to an increase in the TA myofiber size of Smn
2B/-
mice [12]. We thus investigated the effect of fasudil on
skeletal muscle and show that TA muscles from fasudil-
treated P21 Smn
2B/- mice display significantly larger
myofibers than vehicle-treated Smn
2B/- mice (Figure 3A,
B). Indeed, both wild type and fasudil-treated Smn
2B/-
mice show similar myofiber sizes (Figure 3A, B). To
determine whether this increase in muscle fiber size was
SMA-dependent, we also compared TA muscles of vehi-
cle- and fasudil-treated Smn
2B/+ phenotypically normal
littermates. This revealed no significant difference in
myofiber size (Figure 3C, D), thus suggesting that fasudil
acts on muscle-specific molecular pathways that are dis-
tinctly perturbed in the SMA mice.
Fasudil-treated muscles display restored myogenin
expression
To assess if fasudil was active in skeletal muscle, we
examined factors downstream of ROCK signaling.
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Page 4 of 14Figure 1 Fasudil increases lifespan of Smn
2B/- mice, independent of weight gain and pen test performance.F a s u d i l( 3 0m g / k gt w i c e
daily) or vehicle (water) was administered by gavage from post-natal (P) day 3 to P21. The different groups analyzed were: untreated wild type
(WT) (n = 10), vehicle-treated Smn
2B/+ (n = 8), fasudil-treated Smn
2B/+ (n = 9), vehicle-treated Smn
2B/- (n = 16) and fasudil-treated Smn
2B/- (n = 7).
(A) Fasudil significantly increases lifespan of Smn
2B/- mice when compared to vehicle-treated Smn
2B/- mice (*P = 0.0251; # indicates death due to
dystocia). Administration of fasudil does not have adverse effects on the lifespan of normal littermates. (B) Fasudil does not prevent the arrest in
weight gain that occurs in vehicle-treated Smn
2B/- mice onwards of P10.(C) Fasudil does not improve the performance of Smn
2B/- mice on the
pen test when compared to vehicle-treated Smn
2B/- mice.
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Page 5 of 14Cofilin 2 is a skeletal muscle-specific actin-regulating
protein and downstream effector of activated ROCK
[31,32]. We thus determined the impact of administrat-
ing fasudil by gavage on skeletal muscle by evaluating p-
cofilin 2 levels in vehicle- and fasudil-treated TA mus-
cles from P21 mice. Interestingly, the TA muscles from
Smn
2B/- mice have significantly higher levels of p-cofilin
2 protein than wild type muscles (Figure 4A, B), sug-
gesting that the RhoA/ROCK pathway is also misregu-
lated in skeletal muscle. Fasudil decreases p-cofilin 2
levels in Smn
2B/- muscle to wild type levels, indicating
t h a ti ti sa c t i v ei nt h eT Am u s c l ea n dr e s t o r e st h en o r -
mal ROCK/p-cofilin 2 levels (Figure 4A, B). We also
show that fasudil does not upregulate Smn expression in
the TA muscles of Smn
2B/- mice (Figure 4C). Thus, con-
sistent with the spinal cord analysis (Figure 2B), it
appears that the beneficial effects of fasudil in skeletal
muscle are most likely Smn-independent.
Recent work from our laboratory suggests that hin-
dlimb muscles from P21 Smn
2B/- mice display defects in
muscle development, as evidenced by the misregulation
of myogenin (JGB, unpublished data), a transcription
factor that plays a well-characterized role in myogenesis
[33]. We thus investigated whether fasudil had any
impact on myogenin levels. Analysis of TA muscles
from P21 mice confirms the increased levels of myo-
g e n i ni ns k e l e t a lm u s c l eo fSmn
2B/- mice compared to
wild type controls (Figure 4D, E). Importantly, fasudil
administration leads to a significant decrease in myo-
genin levels in Smn
2B/- mice (Figure 4D, E). In fact,
myogenin levels in fasudil-treated TA muscles are
restored to wild type levels.T h u s ,f a s u d i lr e t u r n st h e
Figure 2 Fasudil activity in the spinal cord is Smn-independent and does not prevent motor neuron loss in the ventral horn region.( A
and B) Spinal cords were obtained from post-natal (P) day 21 untreated wild type (WT), vehicle-treated Smn
2B/- and fasudil-treated Smn
2B/- mice.
(A) Immunoblot analysis shows that spinal cords treated with the rho-kinase (ROCK) inhibitor fasudil have decreased levels of p-cofilin, a known
substrate of ROCK. (B) Immunoblot analysis shows that fasudil does not increase Smn protein levels in the spinal cords of Smn
2B/- mice. (C and
D) Spinal cord sections were analyzed from P21 untreated wild type (WT) (n = 3), vehicle-treated Smn
2B/- (n = 3) and fasudil-treated Smn
2B/- (n =
3) mice. (C) Representative images of hematoxylin and esoin (H&E)- and HB9-stained spinal cord sections. Arrowhead depicts a typical large
motor neuron. Scale bar = 50 μm. (D) Quantification of motor neurons within the ventral horn region of the spinal cord shows that fasudil does
not prevent the motor neuron loss that occurs in vehicle-treated Smn
2B/- mice (*P < 0.05; **P < 0.01; NS = not significant; data are mean +/- s.
d.).
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fasudil may increase muscle size by restoring the typical
development of skeletal muscle.
Fasudil does not ameliorate the pre-synaptic phenotype
of NMJs from Smn
2B/- mice
We have previously identified pre-synaptic pathology
at the NMJ in the TVA of the Smn
2B/- mice, as evi-
denced by a loss of pre-synaptic inputs and accumula-
tion of neurofilaments [23]. To determine if the
reduction in muscle pathology observed following fasu-
dil administration could be secondary to reduced
pathology at the NMJ, an in-depth analysis was per-
formed. This analysis was done on the TVA muscle of
P21 late-symptomatic mice, which has previously been
shown to display marked NMJ loss and pre-synaptic
abnormalities [23]. The degree of pre-synaptic swelling,
identified by neurofilament (NF) and synaptic vesicle 2
(SV2) staining, was classified into four categories based
on morphology (type 1: normal, no pre-synaptic
swelling observed; type 2: swollen, pre-synaptic term-
inal arborization is thickened compared to type 1; type
3: spheroid accumulations, spherical swellings accumu-
late over the NMJ; type 4: spheroid covers endplate
(EP), spherical accumulations obscure the entire EP)
(Figure 5A). While more than 80% of wild type term-
inals displayed a ‘normal’ pre-synaptic morphology, in
both vehicle- and fasudil-treated Smn
2B/- mice we
observed a high level of pre-synaptic swelling, with
more than 50% of EPs displaying morphologies classi-
fied as types 2 to 4 (Figure 5B). Quantification of the
number of fully innervated NMJs shows a significant
decrease in both vehicle- and fasudil-treated Smn
2B/-
mice when compared to wild type, with no significant
difference observed between vehicle- and fasudil-trea-
ted SMA mice (Figure 5C). Thus, it appears, at least in
P21 animals, that fasudil does not ameliorate the pre-
synaptic phenotype observed in Smn
2B/- mice. This
suggests that the improvement in muscle pathology we
observe after fasudil administration is unlikely to be
Figure 3 Fasudil increases tibialis anterior (TA) myofiber size. TA muscles were isolated from post-natal (P) day 21 untreated wild type (WT)
(n = 3), vehicle-treated Smn
2B/+ (n = 3), fasudil-treated Smn
2B/+ (n = 3), vehicle-treated Smn
2B/- (n = 6) and fasudil-treated Smn
2B/- (n = 6) mice.
(A) Representative images of cross-sections of WT, or vehicle- and fasudil-treated Smn
2B/- TA muscles stained with hematoxylin and eosin. Scale
bar = 50 μm. (B) Quantification shows that fasudil-treated Smn
2B/- TA muscles display significantly larger myofibers than vehicle-treated Smn
2B/-
mice. (**P < 0.01; ***P < 0.001; NS = not significant; data are mean +/- s.d.). (C) Representative images of cross-sections of vehicle- and fasudil-
treated Smn
2B/+ TA muscles stained with hematoxylin and eosin. Scale bar = 50 μm. (D) Quantification shows that fasudil does not significantly
increase the myofiber size of Smn
2B/+ normal mice (NS = not significant; data are mean +/- s.d.).
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a direct effect on the muscle.
Fasudil increases endplate area of Smn
2B/- NMJs
We have previously shown that Y-27632 administration
significantly increases the EP area of NMJs within the
TA skeletal muscle [12]. We thus assessed the effect of
f a s u d i lo nE Ps i z ei nb o t ht h eT Aa n dt h eT V Ao fP 2 1
mice. Fasudil-treated Smn
2B/- mice had significantly lar-
ger TA and TVA EP areas than vehicle-treated Smn
2B/-
mice (Figure 6). Interestingly, this increase in EP area
was weight-independent, since both vehicle- and fasudil-
treated Smn
2B/- mice display similar weight curves (Fig-
ure 1B). Our results suggest that while fasudil does not
ameliorate the pathology evident at the pre-synaptic
compartment of P21 Smn
2B/- NMJs (Figure 5), there is a
dramatic increase in the size of the post-synaptic com-
partment of NMJs within both muscles investigated
(Figure 6). Together, these results are consistent with
the beneficial effects of fasudil being primarily mediated
by the muscle and not the motor neuron.
Increased NMJ maturation is observed in aging fasudil-
treated Smn
2B/- mice
Although we saw no improvement in pre-synaptic NMJ
pathology in P21 Smn
2B/- mice, we wanted to evaluate
the effect of fasudil over time on NMJ pathology. NMJs
from the TVA muscle of P21 Fasudil-treated Smn
2B/-
mice were compared to those of six month old fasudil-
treated Smn
2B/- mice. Interestingly, we observed a
marked decrease in pre-synaptic pathology in six month
old mice compared to P21 mice, as evidenced by an
increase in the percentage of fully occupied EPs (Figure
7A, B). This was accompanied by a dramatic increase in
EP maturation (Figure 7C, D). We, therefore, suggest
that although there was no initial improvement in the
Figure 4 Fasudil administration inhibits ROCK in skeletal muscle and restores normal myogenin expression levels. Tibialis anterior (TA)
muscles were isolated from post-natal (P) day 21 untreated wild type (WT) (n = 4), vehicle-treated Smn
2B/- (n = 4) and fasudil-treated Smn
2B/- (n
= 4) mice. (A) Immunoblot analysis of p-cofilin 2, a muscle-specific downstream substrate of ROCK, shows that its levels are increased in the TA
muscles of Smn
2B/- mice compared with wild type. Furthermore, this experiment shows that fasudil inhibits ROCK in the TA muscle of Smn
2B/-
mice, and reduces the p-cofilin 2 levels to wild type levels. (B) Quantification shows that wild type TA muscles have significantly less p-cofilin 2
than vehicle-treated Smn
2B/- TA muscles, and that fasudil is active in skeletal muscle and restores p-cofilin 2 to normal levels. (*P < 0.05; NS = not
significant; data are mean +/- s.d.). (C) Immunoblot analysis shows that fasudil does not increase Smn protein levels in the TA muscles of Smn
2B/-
mice. (D) Immunoblot analysis shows that fasudil results in a decrease in myogenin protein levels in fasudil-treated Smn
2B/- TA muscles when
compared to vehicle-treated Smn
2B/- mice. (E) Wild type muscle has significantly less myogenin than vehicle-treated Smn
2B/- TA muscles. Fasudil
administration to Smn
2B/- mice restores myogenin to normal levels (*P < 0.05; NS = not significant; data are mean +/- s.d.).
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Page 8 of 14morphological aspects on NMJ pathology, given suffi-
cient time, fasudil administration allows for the
improved maturation of NMJs in Smn
2B/- mice.
Discussion
Previous work has implicated the RhoA/ROCK path-
way in SMA pathogenesis [10,12,17]. In the present
study, we demonstrate that targeting the ROCK path-
way with the inhibitor fasudil significantly increases
the lifespan of the Smn
2B/- SMA mice. The increased
survival is independent of Smn expression, weight
gain, pen test performance and pre-synaptic NMJ phe-
notype. We find, however, that fasudil benefits post-
synaptic pathology and muscle development. Impor-
tantly, the results obtained from other fasudil clinical
trials are proof-of-principle of its feasibility and avail-
ability as a therapeutic approach for the treatment of
SMA. Future SMA clinical endeavors should therefore
consider assessing the beneficial potential of ROCK
inhibitors.
Figure 5 Fasudil does not improve pre-synaptic neuromuscular junction (NMJ) phenotype of Smn
2B/- mice. Pre-synaptic morphology was
analyzed in the transversus abdominis (TVA) muscle of post-natal (P) day 21 untreated control littermates (n = 3), vehicle-treated Smn
2B/- (n = 6)
and fasudil-treated Smn
2B/- (n = 4) mice. (A) Representative images of NMJs depicting the pre-synaptic morphology categories: normal (type 1),
swollen (type 2), spheroid accumulation (type 3) and spheroids covers the endplate (EP) (type 4). (Neurofilament (NF) and synaptic vesicle
protein 2 (SV2): green; EP: red (BTX)). (B) Quantification of the pre-synaptic morphology shows that control littermates have significantly more
‘normal’ (type 1) NMJs than both vehicle- and fasudil-treated Smn
2B/- mice (**P < 0.01; ***P < 0.001; NS = not significant; data are mean +/- s.d.).
C) Quantification of the fully innervated NMJs shows that both vehicle- and fasudil-treated Smn
2B/- muscles display significantly fewer fully
innervated NMJs than control littermates, with no significant difference between vehicle or Ffsudil treated Smn
2B/- mice (*P < 0.05; ***P < 0.001;
NS = not significant; data are mean +/- s.d.). BTX, a-bungarotoxin.
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Page 9 of 14Smn protein levels remained significantly low in both
fasudil-treated spinal cord and muscle samples of SMA
mice. These findings are important when considering
therapeutic avenues for SMA. There are presently many
strategies being developed to increase the expression of
SMN, such as gene therapy, modulation of transcription
and splicing of SMN2, and the use of various histone
deacetylase (HDAC) inhibitors (reviewed in [34-36]).
Although these therapeutic approaches show promising
results, they remain in pre-clinical stages and may not
be as efficient if administered to mid- to late-sympto-
matic patients [37]. It is therefore crucial to understand
the pathological molecular pathways that are affected
upon SMN loss and how these can be modulated to
attenuate their degenerative effects. Along with other
research groups, we have shown that the RhoA/ROCK
pathway is indeed perturbed in SMA cellular and animal
models and that its targeting leads to a significant bene-
ficial outcome [10,12,17].
We had previously identified the upregulation of RhoA-
GTP in the spinal cords of Smn
2B/- mice [12]. The misre-
gulated RhoA/ROCK pathway in the spinal cord was,
therefore, the primary target of our Fasudil therapeutic
strategy [12]. Interestingly, we have observed that fasudil
does not prevent the motor neuron loss that occurs in the
Smn
2B/- mice. In fact, the most apparent effects of fasudil
appear to be the restoration of normal skeletal muscle
growth and development, as well as increased post-synap-
tic EP area. A number of recent reports suggest that the
SMN protein may have a muscle-intrinsic role that
influences SMA pathology ([28-30] and JGB, unpublished
data). Active RhoA has previously been shown to posi-
tively regulate the expression of myogenin [38,39].
Furthermore, work performed in avian and murine myo-
blasts shows that inhibition of ROCK promotes exit from
the cell cycle and subsequent terminal differentiation [40].
Indeed, myoblasts treated with the ROCK inhibitor Y-
27632 display increased differentiation, cell fusion and
myotube formation [40]. Fasudil’s inhibition of the RhoA/
ROCK pathway most likely restores the normal skeletal
muscle developmental program of Smn
2B/- mice via modu-
lation of myoblast differentiation and fusion, as well as
myogenin expression. The fasudil-dependent increase in
myofiber size could lead to the subsequent increase in EP
size. Indeed, a positive correlation has previously been
established between myofiber size and motor EP size [41].
Furthermore, various reports suggest that post-synaptic
differentiation and formation is initially muscle-dependent
and motor axon-independent [42,43]. Our study, there-
fore, highlights two important points. Firstly, therapeutic
strategies that improve skeletal muscle and EP growth
should be considered when developing therapies for SMA.
Secondly, ROCK inhibition may have positive outcomes in
other pre-clinical disease models characterized by muscle
atrophy and NMJ pathology.
Intriguingly, the dramatic increase in skeletal muscle
myofiber size of fasudil-treated Smn
2B/- mice is not
accompanied by changes in weight or strength, when
compared to vehicle-treated Smn
2B/- mice. Previous stu-
dies have reported this phenomenon, providing a variety
Figure 6 Fasudil increases endplate (EP) area in the tibialis anterior (TA) and transversus abdominis (TVA) muscles.M u s c l e sw e r e
isolated from post-natal (P) day 21 untreated control littermates (n = 3), vehicle-treated Smn
2B/- (n = 4) and fasudil-treated Smn
2B/- mice (n = 3).
(A) Representative images of TA and TVA EPs stained with a-bungarotoxin (BTX). Scale bars = 25 μm (TA) and 30 μm (TVA). (B) Quantification of
EP area shows that fasudil-treated Smn
2B/- TA and TVA muscles display significantly larger EPs when compared to vehicle-treated Smn
2B/-
muscles. (***P < 0.001; ****P < 0.0001; data are mean +/- s.d.).
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Page 10 of 14Figure 7 Aging fasudil-treated Smn
2B/- mice display mature neuromuscular junctions (NMJs). Transversus abdominis (TVA) muscles were
isolated from post-natal (P) day 21 (n = 6) and 6-month -old (n = 4) fasudil-treated Smn
2B/- mice. (A) Representative images of TVA muscles
from P21 and 6-month-old fasudil-treated Smn
2B/- mice. (Neurofilament (NF) and synaptic vesicle protein 2 (SV2): green; EP: red (BTX)). Scale bar
=3 0μm. B) Types of EP occupation were categorized and quantified as fully occupied (where the pre-synaptic terminal completely covers the
EP), partial (where the pre-synaptic terminal partially covers the EP), or vacant (where no pre-synaptic terminal is present at an EP). Surviving 6-
month-old fasudil-treated Smn
2B/- mice display significantly more fully occupied EPs than P21 fasudil-treated Smn
2B/- mice (**P = 0.0096; data are
mean +/- s.d.). (C) Representative images of EP morphology categorization from mature to immature: pretzel, perforated, bright lines and
uniform. EPs are visualized with BTX. (D) Quantification shows that 6-month-old fasudil-treated Smn
2B/- mice display significantly more mature
pretzel-shaped EPs than P21 fasudil-treated Smn
2B/- mice (****P < 0.0001); data are mean +/- s.d.). BTX, a-bungarotoxin; EP, endplate.
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Page 11 of 14of potential explanations. In cases of sarcoplasmic
hypertrophy, the non-contractile myofiber components
expand while muscular strength remains unchanged
[44]. Further, the characterization of a post-natal myo-
genin knockout mouse model revealed normal skeletal
muscle size albeit with a 30% weight loss compared to
control littermates [45]. The authors suggest that this
phenotype is caused by a slower growth rate and per-
turbed energy homeostasis [45]. Finally, Rehfeldt et al.
showed that mice homozygous for the Compact myosta-
tin mutation (C/C) display muscular hyperplasia and
increased muscle weight but with a reduction in overall
body weight [46]. The authors also identify a reduction
in the number of capillaries per muscle in the C/C
mice, subsequently impacting oxidative metabolism [46].
Interestingly, recent work in the severe SMA mouse
model demonstrated a significant decrease in the capil-
lary bed density within skeletal muscle [47]. Thus, the
findings mentioned above highlight the fact that an
increase in muscle size and or weight does not necessa-
rily positively correlate with an increase in body weight.
Regardless, the restoration of myofiber growth and ske-
letal muscle development by fasudil, in the absence of
weight gain, appears to be sufficient to provide thera-
peutic benefits to the Smn
2B/- mice.
In recent years, it has been postulated that SMA may be
a die-back neuropathy, where the motor axons initially
reach the EP but subsequently retract as disease progresses
[48-50]. This hypothesis suggests that synapses are selec-
tively vulnerable in SMA, with synapse loss preceding cell
body degeneration. In addition, it has been suggested that
neurons undergo compartmental degeneration, where the
soma, axons and synapses of neurons possess specific and
compartmentalized mechanisms of degeneration [51-53].
It therefore follows that therapeutics which target distal
compartments of the cell, such as the synapse or axon, can
be protective to the cell body. In our study, we show that
while fasudil administration has little impact upon the
initial loss of motor neurons, it dramatically increases
myofiber and EP size in SMA mice. We therefore suggest
that this improvement in post-synaptic parameters stabi-
lizes the synaptic connections and subsequently protects
the remaining motor neurons. Consistent with this obser-
vation, the surviving synapses constitute NMJs that will
eventually develop and mature normally. Given the tight
correlation between EP maturation and neuromuscular
activity (reviewed in [54]), fasudil may indirectly improve
NMJ transmission, subsequently ameliorating motor EP
maturation. Alternatively, considering the crucial role of
the actin cytoskeleton in the redistribution of acetylcholine
receptors (AChRs) during post-synaptic remodeling
[55,56], fasudil’s modulation of actin dynamics could
directly restore normal AChR clustering. Clearly, the
understanding and identification of fasudil’s influence on
NMJ maturation in SMA mice requires further investiga-
tion. Nevertheless, our work highlights the applicability of
the compartmental degeneration hypothesis to SMA
pathogenesis and the potential of therapies aimed at pre-
venting synaptic degeneration.
ROCK has evolved as an important therapeutic target
in various models of cardiovascular disease, spinal cord
injury and glaucoma (reviewed in [57-59]). Furthermore,
the ROCK inhibitor fasudil, which has been approved in
US clinical trials, has shown beneficial effects in patients
with vasospastic angina [60], stable effort angina [61],
general heart failure [62] and pulmonary hypertension
[63]. It has now become evident that the pathogenic
misregulation of the RhoA/ROCK pathway in various
Smn-depleted cellular and animal models can also be
modulated by the ROCK inhibitors Y-27632 and fasudil,
leading to significant positive outcomes [10,12,17].
Conclusions
The administration of fasudil to SMA mice significantly
increases their lifespan without an obvious increase in
Smn expression or preservation of spinal cord motor
neurons. In fact, fasudil improves post-synaptic and ske-
letal muscle development. Our work underscores the
importance of muscle as a therapeutic target in SMA
and highlights the beneficial potential of ROCK inhibi-
tors as a therapeutic strategy for SMA and for other
degenerative diseases characterized by muscular atrophy
and postsynaptic immaturity.
Additional material
Additional file 1: Effect of low and high doses of fasudil. A low dose
of fasudil (30 mg/kg once daily), a high dose of fasudil (30 mg/kg twice
daily from P3-P6; 50 mg/kg twice daily from P7-P13; 75 mg/kg twice
daily from P14-P21), or vehicle (water) was administered by gavage. The
different groups analyzed were: untreated wild type (WT) (n = 10), fasudil
(high dose)-treated Smn
2B/+ (n = 16), vehicle-treated Smn
2B/- (n = 16),
fasudil (low dose)-treated Smn
2B/- (n = 6) and fasudil (high dose)-treated
Smn
2B/- (n = 10) mice. A) Survival curves show that the low fasudil
dosage regimen had no effect while the high fasudil dosage regimen
significantly increases the lifespan of Smn
2B/- mice when compared to
vehicle-treated Smn
2B/- mice (*P = 0.03; # indicates death due to
malocclusion of the teeth). B) Survival curve shows that the high fasudil
dosage regimen has non-negligible toxic effects on both Smn
2B/- mice
and the normal Smn
2B/+ littermates.
Additional file 2: Smn
2B/- mice treated with fasudil show improved
gait and movement. A movie of aging fasudil- (left mouse) and vehicle-
treated (right mouse) Smn
2B/- mice (two months of age). The fasudil-
treated mouse displays the agility and ability to freely walk and move
around the cage while still displaying a minor neurological phenotype.
The vehicle-treated Smn
2B/- mouse displays a severe neurological
phenotype and reduced motor functions.
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